Stocktoria
Bayer Aktiengesellschaft BAYN.DE
DE · Deutsche Börse Xetra · XETR · stock · Healthcare · website
Bayer Aktiengesellschaft financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $45.6B | $46.6B | $47.6B | $50.7B |
| Gross profit | $26.8B | $25.3B | $27.9B | $30.9B |
| R&D expense | $5.8B | $6.2B | $5.4B | $6.6B |
| SG&A expense | $14.7B | $15.9B | $14.9B | $16.9B |
| Operating income | $6.1B | $3.3B | $8.0B | $7.3B |
| Interest expense | $2.3B | $2.4B | $2.0B | $1.9B |
| Income tax | $466.0M | $212.0M | $1.3B | $504.0M |
| Net income | -$3.6B | -$2.6B | -$2.9B | $4.2B |
| EPS (diluted) | $-3.68 | $-2.60 | $-2.99 | $4.22 |
| Operating cash flow | $5.9B | $7.4B | $5.1B | $7.1B |
| Free cash flow | $3.4B | $4.6B | $2.4B | $4.1B |
| Cash & equivalents | $6.7B | $6.2B | $5.9B | $5.2B |
| Inventory | $12.3B | $13.4B | $13.9B | $13.6B |
| Total assets | $104.5B | $110.8B | $116.3B | $124.9B |
| Total liabilities | $78.5B | $78.8B | $83.2B | $86.0B |
| Shareholders' equity | $25.9B | $31.9B | $32.9B | $38.8B |
Growth · year-over-year · Revenue CAGR -3.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | -2.2% | -2.2% | -6.1% | — |
| Net income growth | — | — | -170.9% | — |
| EPS growth | — | — | -170.9% | — |
| Free cash flow growth | -25.0% | +94.0% | -42.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · DE · as of 2025-12-31. Figures in EUR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.